ImmuCell (ICCC) Projected to Post Earnings on Thursday

Key Points

• ImmuCell is scheduled to report Q1 2026 results after the market close on May 14; analysts expect EPS of $0.05 and revenue of $5.401 million, with a conference call on May 15 at 9:00 AM ET.
• Shares trade around $8.66 with a market cap of about $78.4M, a negative P/E (-78.72), a 1‑year range of $4.52–$9.08, and strong liquidity (current ratio 4.26, quick ratio 1.93).
• Weiss Ratings recently downgraded ImmuCell to a Sell, MarketBeat shows an average rating of Sell, while institutional ownership is roughly 13.47% and Geode Capital modestly increased its stake.

ImmuCell (NASDAQ:ICCC - Get Free Report) is expected to release its Q1 2026 results after the market closes on Thursday, May 14th. Analysts expect ImmuCell to post earnings of $0.05 per share and revenue of $5.4010 million for the quarter. Interested persons can find conference call details on the company's upcoming Q1 2026 earning report page for the latest details on the call scheduled for Friday, May 15, 2026 at 9:00 AM ET.

ImmuCell Stock Performance

NASDAQ:ICCC opened at $8.66 on Thursday. The company has a debt-to-equity ratio of 0.28, a current ratio of 4.26 and a quick ratio of 1.93. The firm has a market capitalization of $78.37 million, a price-to-earnings ratio of -78.72 and a beta of 0.50. The company's 50-day moving average is $6.98 and its two-hundred day moving average is $6.34. ImmuCell has a 1-year low of $4.52 and a 1-year high of $9.08.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings downgraded shares of ImmuCell from a "hold (c-)" rating to a "sell (d-)" rating in a research note on Monday, April 6th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, ImmuCell currently has an average rating of "Sell".

Institutional Investors Weigh In On ImmuCell

A hedge fund recently raised its stake in ImmuCell stock. Geode Capital Management LLC grew its stake in ImmuCell Corporation (NASDAQ:ICCC - Free Report) by 4.2% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 71,852 shares of the biotechnology company's stock after acquiring an additional 2,907 shares during the period. Geode Capital Management LLC owned about 0.79% of ImmuCell worth $500,000 as of its most recent filing with the SEC. 13.47% of the stock is currently owned by institutional investors.

About ImmuCell

ImmuCell Corporation NASDAQ: ICCC is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.

The company's flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.